Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Europe's STOXX 600 marks third month of gains on earnings, recovery hopes

04/30/2021 | 12:06pm EDT
The German share price index DAX graph is pictured at the stock exchange in Frankfurt

(Reuters) - European stocks ended lower on Friday after dismal GDP data, but marked a third straight month of gains on strong corporate earnings and optimism about an economic recovery from the COVID-19 pandemic.

The pan-regional STOXX 600 index fell 0.3%, hovering below its all-time high, and ending the month 1.8% higher.

Data showed the euro zone economy dipped into a second technical recession after a smaller than expected contraction in the first quarter, but is now set for recovery as pandemic curbs are lifted amid accelerating vaccination campaigns.

The German economy contracted by a greater-than-expected 1.7%, hit by renewed lockdowns, while the French economy grew more than expected.

But strong earnings showed companies in the euro zone were well on their way to recover from the impact of the pandemic.

AstraZeneca jumped 4.3% as the British drugmaker posted better-than-expected results and forecast second half growth.

Swedish Match rose 0.7% after the tobacco group reported a much higher first-quarter operating profit than expected, helped by growth in its Smokefree product segment. UK peers British American Tobacco and Imperial Brands rose more than 2% each.

Broadly, European earnings have come in much stronger than expected, with a higher than usual 71% of companies beating profit expectations in the first quarter, according to Refinitiv IBES data. A third of STOXX 600 companies have published results so far.

"Expectations are high, companies are beating even these elevated expectations, and yet the market is responding with caution," Lewis Grant, portfolio manager at Federated Hermes, wrote in a note.

"At current valuations, and with much pandemic related uncertainty remaining, many investors are more concerned about downside than upside."

Strong earnings from British firms helped the European retailers sector outpace its peers in April with a 6.7% bounce, while automobile stocks lagged as a global semiconductor shortage hurt production.

Banking stocks came under pressure on Friday as euro zone bond yields eased from their highest level since January 2020. But the sector raced past its peers this week with a near 6% gain, driven by a swathe of strong earnings.

Barclays tumbled 7% despite reporting a quarterly profit that more than doubled, while France's BNP Paribas slipped 0.8% on higher costs.

Spain's Banco Sabadell jumped 8.7% to the top of the STOXX 600 after its quarterly profit beat market expectations, helped by strength in its British unit TSB.

(Reporting by Sruthi Shankar in Bengaluru; Editing by Shounak Dasgupta and Mark Potter)

By Sruthi Shankar and Ambar Warrick

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.11% 8268 Delayed Quote.13.01%
BANCO DE SABADELL, S.A. 1.49% 0.5864 Delayed Quote.63.22%
BARCLAYS PLC -0.98% 174.5 Delayed Quote.20.14%
BNP PARIBAS -1.19% 51.45 Real-time Quote.20.80%
BRITISH AMERICAN TOBACCO PLC -1.56% 2680.5 Delayed Quote.0.55%
IMPERIAL BRANDS PLC -0.52% 1542 Delayed Quote.0.94%
SWEDISH MATCH AB 1.00% 77.08 Delayed Quote.19.66%
All news about ASTRAZENECA PLC
11:43aASTRAZENECA : H1 2021 results
11:43aASTRAZENECA : NHS - Presidential visit strengthens healthcare partnership with K..
10:42aASTRAZENECA : US authorities probing Emergent BioSolutions over COVID-19 vaccine..
09:06aASTRAZENECA : Shortages Hamper Ohangwena Vaccination Drive
06:47aASTRAZENECA : Receives a Buy rating from Credit Suisse
07/29ASTRAZENECA : Emergent to resume J&J COVID-19 vaccine production at Baltimore pl..
07/29Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - exe..
07/29AstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges
07/29ASTRAZENECA : to seek US approval of COVID vaccine in 2nd half
07/29ASTRAZENECA : COVID-19 Jabs Supplied to Canada, Mexico From US Before Inspection..
More news
Financials (USD)
Sales 2021 34 470 M - -
Net income 2021 5 907 M - -
Net Debt 2021 26 467 M - -
P/E ratio 2021 21,8x
Yield 2021 3,41%
Capitalization 128 B 178 B -
EV / Sales 2021 4,48x
EV / Sales 2022 3,56x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 82,68 $
Average target price 133,66 $
Spread / Average Target 61,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.01%179 111
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%335 069
PFIZER, INC.16.25%239 525
NOVARTIS AG-0.16%224 495